Drug Type TCR-T Cell therapy |
Synonyms CD8+-T-cells-Immatics N.V., IMA 101, IMA-101 + [1] |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapsed Solid Neoplasm | Phase 1 | United States | 30 Jun 2017 | |
Solid tumor | Phase 1 | United States | 26 Jun 2017 |
Phase 1 | 9 | pbhnrvrcjv(zpobsiqacx) = cytopenias associated with the lymphodepleting regimen and Grade 1-2 cytokine release syndrome gnssgvhrwb (xywrhaefqm ) | Positive | 19 Jul 2019 |